Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality.

PLoS One · 2008 · PMC2481284 · PMID 18648539

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

However, a recent meta-analysis of clinical trial outcomes for the PPARγ agonist rosiglitazone found a significant increase in the risk of myocardial infarction, and a borderline significant risk of death from cardiovascular causes [4] .

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.